Pluri (PLUR) said Wednesday that it signed an exclusive collaboration deal with Hemafund, an umbilical cord blood bank, for the distribution and clinical advancement of PLX-R18 cell therapy as a potential treatment for Hematopoietic Acute Radiation Syndrome in Ukraine.
Pluri said it has agreed to produce and supply PLX-R18 and will work with Hemafund to seek funding for the production of an initial 12,000 doses of PLX-R18 to be stored and managed by Hemafund.
The companies plan to sign a separate definitive agreement once the external funding is secured. The collaboration could fetch over $100 million in value for the companies based on the estimated cost and the expected initial stockpile, Pluri said.
The three-year agreement can be extended for three more years, the company said.
Shares of Pluri were up 8.8% in recent Wednesday trading.
Price: 4.69, Change: +0.38, Percent Change: +8.82
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。